The end of the Humira era

Humira's 20-year exclusivity period comes to an end this week, as the first biosimilar version hits the US market. The anti-TNF antibody has generated more than $200bn in global sales since launch, and analysts reckon it will be a blockbuster for a few years yet, thanks to Abbvie’s powerful grip on the US market.